Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Oligometastatic Prostate Cancer
NCT05893381Phase 2Recruiting
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jun 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 PSMA I&T in prostate cancer (PCa), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Jun 2023; status: recruiting.
02
Drugs
lutetium Lu 177 PSMA I&T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05893381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05893381.